Technical Analysis for ADMS - Adamas Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 5.99 -0.33% -0.02
ADMS closed down 0.33 percent on Wednesday, July 17, 2019, on 2.2 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Flat
See historical ADMS trend table...

Date Alert Name Type % Chg
MACD Bearish Signal Line Cross Bearish 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.84%
Inside Day Range Contraction -0.17%
Wide Bands Range Expansion -0.17%
Spinning Top Other 0.00%
Wide Bands Range Expansion 0.00%
Wide Bands Range Expansion -1.80%

Older signals for ADMS ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Adamas Pharmaceuticals, Inc. focuses on the development and commercialization of therapeutics for chronic disorders of the central nervous systems (CNS) in the United States. The company is developing its lead product candidate, ADS-5102 that has completed a Phase 2/3 clinical study for levodopa induced dyskinesia, a complication of Parkinson's disease; and as a treatment for chronic behavioral symptoms associated with traumatic brain injury. It is also developing ADS-8800 and ADS-9000 series of products for use in a range of CNS indications; ADS-8704, a fixed-dose combination of memantine and donepezil for the treatment of moderate to severe dementia related to alzheimer's disease; and ADS-8902, a triple combination antiviral drug therapy for influenza. In addition, the company develops memantine-based therapeutics portfolio includes Namenda XR and MDX-8704, which are used in the treatment of dementia associated with moderate to severe alzheimer's disease. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.
Chemical Compounds Alzheimer's Disease Influenza Parkinson's Disease Psychiatry Psychiatric Diagnosis Dementia Treatment Of Alzheimer's Disease Cognitive Disorders Drug Therapy Chronic Disorders Learning Disabilities Levodopa Induced Dyskinesia Traumatic Brain Injury
Is ADMS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 29.49
52 Week Low 4.2
Average Volume 403,084
200-Day Moving Average 9.1094
50-Day Moving Average 5.4136
20-Day Moving Average 5.8785
10-Day Moving Average 5.973
Average True Range 0.2765
ADX 25.81
+DI 23.724
-DI 16.838
Chandelier Exit (Long, 3 ATRs ) 5.5305
Chandelier Exit (Short, 3 ATRs ) 5.3695
Upper Bollinger Band 6.3303
Lower Bollinger Band 5.4267
Percent B (%b) 0.62
BandWidth 15.371268
MACD Line 0.1833
MACD Signal Line 0.1833
MACD Histogram 0.0
Fundamentals Value
Market Cap 134.86 Million
Num Shares 22.5 Million
EPS -2.99
Price-to-Earnings (P/E) Ratio -2.00
Price-to-Sales 2373.51
Price-to-Book 4.03
PEG Ratio -0.06
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.19
Resistance 3 (R3) 6.18 6.10 6.15
Resistance 2 (R2) 6.10 6.05 6.11 6.14
Resistance 1 (R1) 6.05 6.02 6.01 6.06 6.13
Pivot Point 5.97 5.97 5.96 5.98 5.97
Support 1 (S1) 5.92 5.92 5.88 5.93 5.85
Support 2 (S2) 5.84 5.89 5.85 5.84
Support 3 (S3) 5.79 5.84 5.83
Support 4 (S4) 5.80